Naoyuki Hayashi

KNTC1 introduces segmental heterogeneity to mitochondria

Atsushi Tsukamura, Hirotaka Ariyama, Naoyuki Hayashi, Satoko Miyatake et autres

Mitochondria contribute to cellular metabolism by providing a specialised milieu for energising cells by incorporating and processing the metabolites. However, heterogeneity between mitochondria has only partially been elucidated. Mitochondria dynamically alter their morphology and function during the life of an animal, when …

jp, pl (code pays fourni par la source)

Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance

Tomohiro Ito, Yusuke Naito, Naoki Shimmoto, Kaori Ochiai et autres

We investigated the long-term safety and effectiveness of linagliptin in Japanese type 2 diabetes (T2D) patients starting linagliptin add-on therapy in routine clinical practice. This 3-year prospective, observational, post-marketing surveillance (PMS) was conducted in Japanese patients starting linagliptin add-on therapy. The primary …

Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance

Tomohiro Ito, Yusuke Naito, Naoki Shimmoto, Kaori Ochiai et autres

BACKGROUND: We investigated the long-term safety and effectiveness of linagliptin in Japanese type 2 diabetes (T2D) patients starting linagliptin add-on therapy in routine clinical practice. RESEARCH DESIGN AND METHODS: This 3-year prospective, observational, post-marketing surveillance (PMS) was conducted in Japanese patients starting …

jp (code pays fourni par la source)

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study

Fumiko F. Yamamoto, Rie Ikeda, Kaori Ochiai, Tetsuaki Hirase et autres

INTRODUCTION: International clinical trials have shown that linagliptin significantly improves glycemic control and can be used at a single dose regardless of renal function in patients with type 2 diabetes (T2D). However, to date, no studies have evaluated the use of linagliptin …

jp (code pays fourni par la source)

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study

Fumiko F. Yamamoto, Yuriko Unno, Tomoo Okamura, Rie Ikeda et autres

INTRODUCTION: Clinical trials of linagliptin in Japanese patients conducted to date have had limited observational periods; therefore, there is a need for additional longer-term real-world data. The aim of this study was to investigate the long-term safety and effectiveness of linagliptin in …

jp (code pays fourni par la source)

Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial

Kohei Kaku, Masakazu Haneda, Hiroyuki Sakamaki, Atsutaka Yasui et autres

PURPOSE: The goal of this study was to assess the cost-effectiveness of empagliflozin in Japan based on the Asian subpopulation in the EMPA-REG OUTCOME trial. METHODS: The trial has shown a reduction in the risk for cardiovascular (CV) and renal events with …

jp, ph, de, us (code pays fourni par la source)

Altered metabolic regulation owing to gsp1 mutations encoding the nuclear small G protein in Saccharomyces cerevisiae

Naoyuki Hayashi, Masaya Oki

jp (code pays fourni par la source)

PDB62 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN JAPAN BASED ON RESULTS FROM THE SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE EMPA-REG OUTCOME TRIAL

Kohei Kaku, Masakazu Haneda, Hiroyuki Sakamaki, Atsutaka Yasui et autres

jp, de, us (code pays fourni par la source)

MicroRNA-140 mediates RB tumor suppressor function to control stem cell-like activity through interleukin-6

Akiyo Yoshida, Shunsuke Kitajima, Fengkai Li, Chaoyang Cheng et autres

// Akiyo Yoshida 1, 2 , Shunsuke Kitajima 1, 3 , Fengkai Li 1 , Chaoyang Cheng 4 , Yujiro Takegami 4 , Susumu Kohno 1 , Yuan Song Wan 1 , Naoyuki Hayashi 1, 5 , Hayato Muranaka 1 , Yuuki …

jp, us (code pays fourni par la source)

Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes

Akiko Sarashina, Christian Friedrich, Susanne Crowe, Sanjay Dhanji Patel et autres

AIMS/INTRODUCTION: The efficacy and safety of drugs can vary between different races or ethnic populations because of differences in the relationship of dose to exposure, pharmacodynamic response or clinical efficacy and safety. In the present post-hoc analysis, we assessed the influence of …

jp, ch, de, gb (code pays fourni par la source)

Oligomeric interaction of hepatitis C virus NS5B is critical for catalytic activity of RNA-dependent RNA polymerase.

Weiping Qin, Hong Luo, Takahiro Nomura, Naoyuki Hayashi et autres

VOLUME 277 (2002) PAGES 2132–2137 This article has been withdrawn by the authors. Possible errors in this manuscript were recently brought to our attention. We examined the images in the article and determined that some parts of two figures could have been …

Comparison between conventional and endoscopic injection in aluminum potassium tannic acid sclerosing therapy

Naoyuki Hayashi, Seiichiro Sugimoto, Yasuaki Miyazaki, Toshiya Michiura et autres

jp (code pays fourni par la source)